NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

KRH-1120, a small- CXCR4 antagonistic nonpeptide molecule, with highly potent and selective anti-HIV-1 activity.

Ichiyama K, Hirose K, Yokoyama S, Bannai K, Edamatsu T, Yanaka M, Niitani M, Yamamoto N; International Conference on AIDS.

Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. WeOrA535.

K. Ichiyama, Tokyo Medical and Dental University, School of Medicine, 1-5-45 Yushima Bunkyo-ku, Tokyo 113 8519, Japan, Tel.: +81 3 580 351 78, Fax: +81 3 580 301 24, E-mail: ichiyama.mmb@med.tmb.ac.jp

Background: To determine the effects of KRH-1120, a nonpeptide compound with a small molecular weight, on the binding of SDF-1 to CXCR4 and T-cell line-tropic HIV-1 replication. Methods: The effects of KRH-1120 on the SDF-1 binding and blocking of Ca2+ signaling were studied with CXCR4-expressing HOS cells. HIV-1 replication was determined in infected and uninfected peripheral blood mononuclear cells (PBMC) and a human T-cell line, MT-4. Several laboratory strains and clinical HIV-1 isolates including X4 (HTLV-IIIB and NL4-3) and R5 (JR-CSF and JR-FL) viruses were utilized for infection. HIV-1 replication was monitored by MTT assay, p24 antigen and HIV-1 mRNA production. Results: KRH-1120 antagonized the binding of SDF-1 to CXCR4 in HOS cells and blocked CXCR4-mediated Ca2+ signaling at nanomolar concentrations The inhibition of alpha-chemokine receptors by KRH-1120 appeared to be specific to CXCR4 because the compound did not affect CCR5, CCR3, or CCR4. Thus, KRH-1120 represented highly potent and selective inhibition of X4 HIV-1 replication without showing any cytotoxicity to the host cells. The compound inhibited the replication of X4 HIV-1 clinical isolates as well as a laboratory strain in PBMC, though it was totally inactive against R5 HIV-1. Conclusions: KRH-1120 is a potent inhibitor HIV-1 replication and is considered to be orally-available based on its chemical structures. Hence, it deserves further investigation as a potential therapeutic agent in the treatment of HIV-1-infected patients in combination with members of drugs utilized in HAART.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Cell Line
  • Chemokine CXCL12
  • Chemokines, CXC
  • HIV-1
  • Humans
  • Receptors, CCR5
  • Receptors, CXCR4
  • Receptors, Chemokine
  • T-Lymphocytes
Other ID:
  • GWAIDS0002612
UI: 102240106

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov